MD Anderson Cancer Research Center
Welcome,         Profile    Billing    Logout  
 3 Trials 
8 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Thompson, Philip
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
NCI-2018-01182, NCT03128879: Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

Recruiting
2
90
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Acalabrutinib
M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia
06/25
06/25
NCT05317936: Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax

Recruiting
2
44
US
Pirtobrutinib, LOXO-305, Venetoclax, ABT-199, GDC-0199
M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
10/27
10/27
ARDENT, NCT05878184: Study Evaluating SC291 in Subjects With r/r B-cell Malignancies

Recruiting
1
57
US, RoW
SC291, Cyclophosphamide, Fludarabine
Sana Biotechnology
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
12/26
12/27
Seiter, Karen
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
SY-1425-202, NCT04905407: Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML

Recruiting
2
95
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals
Acute Myeloid Leukemia
04/28
04/28
NCT04072458: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

Recruiting
1
30
US
L-Bcl-2 antisense oligonucleotide, BP1002
Bio-Path Holdings, Inc.
Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Marginal Zone Lymphoma, Hodgkin Lymphoma, Waldenstrom Macroglobulinemia, DLBCL
09/24
01/26

Download Options